Zepatier grazoprevir/elbasvir: Phase III data

Zepatier is approved in the U.S. to treat chronic HCV genotypes 1 and 4 infection. An MAA for Zepatier to treat chronic HCV infection is under EMA review with a decision expected in mid-2016. ...